The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
His appointment is expected to strengthen scientific input in policy discussions across public health, biotech, and translational research
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Collaboration to drive diagnostics exports, tap high-growth regional markets and build scalable commercialization platform
Subscribe To Our Newsletter & Stay Updated
